Marjac /triple Marjac. thx for the response. I agree a settlement is not viable at the present time ...BUT becomes viable once AMRN wins right of appeal .
Should the case proceed they will both end up in court early 2021 at which time nether side can be 100% assured of a win and can consider settlement options right up to the time the 3 judges render their decision .
Triple. Teva is the big dog in this ....large company , economies of scale , established market re existing Lovaza sales . Doubt if any other small generic would file or be willing to compete with them in this market . One key will be who BASF signs with ....regarding providing API
You have to have the API supply ( raw EPA ) to compete ...something poster Will Lar has looked into
Market Data 
Markets 
AI
